© 2008

Cancer Proteomics

From Bench to Bedside

  • Sayed S. Daoud
  • Comprehensive look at the use of proteomic strategies in cancer therapy

  • Covers all the latest technologies used in proteomics

  • Includes in-depth information on the human proteome and the role of the FDA in regulating the use of proteomics

  • The latest research on proteomics and tyrosine kinases

  • p53 signalling and tumor biomarkers

  • Discusses the future uses of proteomics in therapeutic individualization and target discovery


Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Proteomics Technologies

    1. Front Matter
      Pages 1-1
    2. Belinda Willard, Suma Kaveti, Michael T. Kinter
      Pages 3-35
  3. Cell Signaling Proteomics

    1. Front Matter
      Pages 37-37
    2. Kyunghee Lee, Tao Wang, Abdur Rehman, Yuhua Wang, Sayed S. Daoud
      Pages 39-57
  4. Tumor Proteomics

    1. Front Matter
      Pages 79-79
    2. Christina M. Annunziata, Dana M. Roque, Nilofer Azad, Elise C. Kohn
      Pages 101-120
    3. Cecilia Sarto, Vanessa Proserpio, Fulvio Magni, Paolo Mocarelli
      Pages 121-137
    4. M.A. Reymond, M. Beshay, H. Lippert
      Pages 139-159
    5. Nils Brünner, Mads Holten-Andersen, Fred Sweep, John Foekens, Manfred Schmitt, Michael J. Duffy
      Pages 189-207
  5. Bioinformatics and Regulatory Aspects of Proteomics

    1. Front Matter
      Pages 209-209
    2. Rolf Apweiler, Michael Mueller
      Pages 211-235
    3. Dave Li, Joseph Hackett, Maria Chan, Gene Pennello, Steve Gutman
      Pages 237-258
  6. Back Matter
    Pages 259-264

About this book


Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.


Bioinformatics Cancer Research Carcinom Oncology Proteomics Translation classification diagnostics proteins

Editors and affiliations

  • Sayed S. Daoud
    • 1
  1. 1.Department of Pharmaceutical SciencesWashington State UniversityPullman

Bibliographic information

  • Book Title Cancer Proteomics
  • Book Subtitle From Bench to Bedside
  • Editors Sayed S. Daoud
  • Series Title Cancer Drug Discovery and Development
  • DOI
  • Copyright Information Humana Press Inc. 2008
  • Publisher Name Humana Press
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-1-58829-858-4
  • Softcover ISBN 978-1-61737-807-2
  • eBook ISBN 978-1-59745-169-7
  • Edition Number 1
  • Number of Pages XII, 264
  • Number of Illustrations 0 b/w illustrations, 5 illustrations in colour
  • Topics Cancer Research
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods


From the reviews:

"This is a comprehensive overview of the current state of knowledge in the area of cancer proteomics … . appropriate for cancer researchers of diverse specialties and clinicians conducting basic or clinical cancer research. … a book that provides a truly comprehensive look at the utility of proteomics from ‘bench to bedside.’ All chapters are well referenced and of appropriate length, and many contain helpful illustrations. … an excellent book that is appropriate for scientists and clinicians with an interest in cancer proteomics." (John D. Robertson, Doody’s Review Service, May, 2008)

"This book … provides the reader with a current perspective and anticipated uses of proteomic strategies in cancer therapy as well as basic cancer research. … the book provides a broad account of the area of cancer proteomics and adequately covers issues relevant to the use of proteomic strategies in clinical research. … The book would be of interest to clinicians and basic cancer researchers … who are already involved in, or who are considering the use of proteomics in their work." (JF Timms, British Journal of Cancer, Vol. 99 (4), 2008)